NDD01, hiPSC_11080401_c1
QBRIi014-A
General
Cell Line |
|
| hPSCreg name | QBRIi014-A |
| Cite as: | QBRIi014-A (RRID:CVCL_C1VV) |
| Alternative name(s) |
NDD01, hiPSC_11080401_c1
|
| Cell line type | Human induced pluripotent stem cell (hiPSC) |
| Similar lines |
IBKMOLi002-A (CACNA1D L271H iPCs) Donor's gene variants: CACNA1D Donor diseases: hyperinsulinemic hypoglycemia Autism Spectrum Disorder Muscle Hypotonia Primary hyperaldosteronism |
| Last update | 2nd October 2022 |
| User feedback | |
Provider |
|
| Generator | Qatar Biomedical Research Institute (QBRI) |
| Derivation country | Qatar |
External Databases |
|
| BioSamples | SAMEA111347413 |
| Cellosaurus | CVCL_C1VV |
| Wikidata | Q114312745 |
General Information |
|
| Publications | |
| * Is the cell line readily obtainable for third parties? |
No |
Donor Information
General Donor Information |
|
| Sex | male |
Phenotype and Disease related information (Donor) |
|
| Diseases | A disease was diagnosed.
|
External Databases (Donor) |
|
| BioSamples | SAMEA111396440 |
Ethics
| Has informed consent been obtained from the donor of the embryo/tissue from which the pluripotent stem cells have been derived? | Yes |
| Was the consent voluntarily given? | Yes |
| Has the donor been informed that participation will not directly influence their personal treatment? | Yes |
| Can you provide us with a copy of the Donor Information Sheet provided to the donor? | Yes |
| Do you (Depositor/Provider) hold the original Donor Consent Form? | No |
| If you do not hold the Donor Consent Form, do you know who does? | Yes |
| Please provide the contact information | falshaban@hbku.edu.qa |
| Please indicate whether the data associated with the donated material has been pseudonymised or anonymised. | pseudonymised |
| Does consent explicitly allow the derivation of pluripotent stem cells? | Yes |
| Does consent prevent CELLS DERIVED FROM THE DONATED BIOSAMPLE from being made available to researchers anywhere in the world? | No |
| How may genetic information associated with the cell line be accessed? | Controlled Access |
| Will the donor expect to receive financial benefit, beyond reasonable expenses, in return for donating the biosample? | No |
| Has a favourable opinion been obtained from a research ethics committee, or other ethics review panel, in relation to the Research Protocol including the consent provisions? | Yes |
| Name of accrediting authority involved? | Qatar Biomedical Research Insttitute |
| Approval number | QBRI-IRB 2018-024 |
| For generation of the cell line, who was the supplier of any recombined DNA vectors or commercial kits used? |
hIPSC Derivation
General |
|
| Source cell type |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
| Source cell origin |
A peripheral blood cell with a single nucleus. This category includes lymphocytes and monocytes.
Synonyms
|
Reprogramming method |
|
| Vector type | Non-integrating |
| Vector | Sendai virus |
Vector free reprogramming |
|
Other |
|
| Derived under xeno-free conditions |
Unknown |
| Derived under GMP? |
Unknown |
| Available as clinical grade? |
Unknown |
Culture Conditions
| Medium |
mTeSR™ 1
|
Characterisation
Analysis of Undifferentiated Cells
| Marker | Expressed | Immunostaining | RT-PCR | Flow Cytometry | Enzymatic Assay | Expression Profiles |
| SOX2 |
Yes |
|
|
|||
| SSEA-4 |
Yes |
|
|
|||
| TRA 1-60 |
Yes |
|
|
|||
| TRA 1-81 |
Yes |
|
|
|||
| NANOG |
Yes |
|
|
|||
| POU5F1 (OCT-4) |
Yes |
|
|
Differentiation Potency
Certificate of Analysis |
|
| Is there a certificate of analysis available? |
Yes
Passage:
|
Genotyping
Karyotyping (Cell Line) |
|
| Has the cell line karyotype been analysed? |
Yes
46,XY[cp20]
|
Other Genotyping (Cell Line) |
|
Login to share your feedback, experiences or results with the research community.